JP2023548855A5 - - Google Patents

Info

Publication number
JP2023548855A5
JP2023548855A5 JP2023526968A JP2023526968A JP2023548855A5 JP 2023548855 A5 JP2023548855 A5 JP 2023548855A5 JP 2023526968 A JP2023526968 A JP 2023526968A JP 2023526968 A JP2023526968 A JP 2023526968A JP 2023548855 A5 JP2023548855 A5 JP 2023548855A5
Authority
JP
Japan
Prior art keywords
approximately
weight
compound
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057996 external-priority patent/WO2022098828A1/en
Publication of JP2023548855A publication Critical patent/JP2023548855A/ja
Publication of JP2023548855A5 publication Critical patent/JP2023548855A5/ja
Pending legal-status Critical Current

Links

JP2023526968A 2020-11-05 2021-11-04 キナーゼ阻害剤の医薬組成物 Pending JP2023548855A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110124P 2020-11-05 2020-11-05
US63/110,124 2020-11-05
PCT/US2021/057996 WO2022098828A1 (en) 2020-11-05 2021-11-04 Pharmaceutical compositions of a kinase inhibitor

Publications (2)

Publication Number Publication Date
JP2023548855A JP2023548855A (ja) 2023-11-21
JP2023548855A5 true JP2023548855A5 (https=) 2024-11-12

Family

ID=78820880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526968A Pending JP2023548855A (ja) 2020-11-05 2021-11-04 キナーゼ阻害剤の医薬組成物

Country Status (16)

Country Link
US (1) US20230398108A1 (https=)
EP (1) EP4240333A1 (https=)
JP (1) JP2023548855A (https=)
KR (1) KR20230104186A (https=)
CN (1) CN116406261A (https=)
AU (1) AU2021374669A1 (https=)
CA (1) CA3196001A1 (https=)
CL (1) CL2023001268A1 (https=)
CO (1) CO2023005942A2 (https=)
CR (1) CR20230223A (https=)
GE (1) GEAP202316262A (https=)
IL (1) IL302485A (https=)
MX (1) MX2023005273A (https=)
PE (1) PE20240223A1 (https=)
TW (1) TW202227061A (https=)
WO (1) WO2022098828A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402114A (zh) * 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030435B1 (ru) * 2010-07-16 2018-08-31 Экселиксис, Инк. ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
US11564915B2 (en) * 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
WO2016079687A1 (en) * 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
CN117402114A (zh) 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
KR102828472B1 (ko) * 2018-12-13 2025-07-03 엑셀리시스, 인코포레이티드 키나아제 억제제의 결정질 형태 및 염 형태
CA3123985A1 (en) * 2018-12-24 2020-07-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound

Similar Documents

Publication Publication Date Title
JP2021512117A5 (https=)
JP5466179B2 (ja) 生物学的利用能が改善されたエンタカポン、レボドパ及びカルビドパの医薬組成物
JP2022542804A5 (https=)
KR20130091319A (ko) 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
US20070104785A1 (en) Tablets of linezolid form iii and processes for their preparation
JP2007503414A5 (https=)
JP2023548855A5 (https=)
CA3104695A1 (en) Formulations of ag10
JP2023536667A5 (https=)
CA2815280C (en) A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
WO2019203752A2 (en) Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent
JP2022532540A (ja) アキシチニブを含有する医薬組成物
US11730753B2 (en) Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride
US20210267908A1 (en) Pharmaceutical compositions of rivaroxaban
JP5651478B2 (ja) 糖アルコールと共微粒子化されたエンタカポンの医薬組成物
AU2013213255A1 (en) Stable amorphous Raltegravir potassium premix and process for the preparation thereof
WO2021091510A1 (en) A capsule comprising eltrombopag olamine
JP7233852B2 (ja) 変色が抑制された固形製剤
WO2011081118A1 (ja) 経口投与用医薬組成物
WO2017037645A1 (en) Stable pharmaceutical formulations of teriflunomide
JP2018184381A (ja) エゼチミブ含有錠剤およびその製法
WO2022039701A1 (en) A solid oral composition comprising eltrombopag choline
AU2007101090A4 (en) Process for the preparation of a solid pharmaceutical dosage form
JP7423297B2 (ja) 口腔内崩壊錠およびその製造方法